Stephen Sonis

Dr. Stephen Sonis is a professor of oral medicine and diagnostic sciences at the Harvard School of Dental Medicine (HSDM), a senior surgeon at Dana-Farber Cancer Institute, and a senior surgeon in oral medicine at Brigham and Women's Hospital. His research focuses on the tissue toxicities associated with cancer therapy.

Sonis has developed translational models used to investigate treatment-related tissue toxicities, informing both the development of new therapies and omics-based approaches to personalizing treatment. He is also recognized for his expertise in clinical trials, and his current academic collaborations examine the financial burden of cancer, including how reimbursement disparities contribute to the financial toxicity of treatment.

He is the former president of Triad, an international nonprofit focused on the health and economic effects of cancer treatment toxicities, and has served as a special government employee of the U.S. Food and Drug Administration. Sonis also founded Biomodels, a preclinical research organization spun out of Brigham and Women's Hospital in 1997, and Primary Endpoint Solutions, a clinical research organization that supports companies throughout the drug development process.

Sonis earned his DMD from Tufts University and completed his DMSc and residency training at HSDM. He then completed postdoctoral training in tumor immunology at the University of Oxford, where he was a Knox Fellow. He holds several patents and has authored more than 350 original publications, reviews, and book chapters, along with 11 books; his work has been cited more than 40,000 times.